Multiple Sclerosis Treatment: World Drug Market 2012-2022
What are the commercial prospects for multiple sclerosis treatment? Visiongain's report shows you potential drug revenues to 2022. Find data, forecasts and discussions.
Discover revenue predictions for multiple sclerosis (MS) treatments at world market, product and national levels to 2022. Our report gives you business research, analysis and data.
How will the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya perform to 2022? You can find potential revenues. Discover information on disease-modifying agents for MS, the main focus of this work.
This study discusses Biogen Idec, Teva, Sanofi, Novartis, Merck Serono, Bayer and other pharmaceutical companies. Receive information you need.
What does the future hold? With a strong R&D pipeline, the MS treatment sector has potential to expand.
The market will change with the launch of new agents that slow symptom progression and reduce relapse rates. Find R&D trends and commercial opportunities there.
Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 56 tables and charts and three research interviews.
Advantages of Multiple Sclerosis Treatment: World Drug Market 2012-2022 for your work
Our report gives you the following information and advantages:
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We tackle crucial questions on MS treatment, helping you to stay ahead.
Gain business research, data and analysis for multiple sclerosis drug treatments
Our report is for everybody needing industry and market analysis for drug-based MS treatment. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Discover revenue predictions for multiple sclerosis (MS) treatments at world market, product and national levels to 2022. Our report gives you business research, analysis and data.
How will the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya perform to 2022? You can find potential revenues. Discover information on disease-modifying agents for MS, the main focus of this work.
This study discusses Biogen Idec, Teva, Sanofi, Novartis, Merck Serono, Bayer and other pharmaceutical companies. Receive information you need.
What does the future hold? With a strong R&D pipeline, the MS treatment sector has potential to expand.
The market will change with the launch of new agents that slow symptom progression and reduce relapse rates. Find R&D trends and commercial opportunities there.
Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 56 tables and charts and three research interviews.
Advantages of Multiple Sclerosis Treatment: World Drug Market 2012-2022 for your work
Our report gives you the following information and advantages:
- Find potential revenue to 2022 for the world MS drug market, viewing sales growth
- Discover revenue forecasts to 2022 for leading MS drugs, assessing commercial potential
- Assess leading companies, discovering their activities and prospects
- See revenue forecasts to 2022 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
- Review R&D for treating MS, seeing pipeline trends
- Investigate competition and opportunities influencing the industry and its sales
- Find out what will stimulate and restrain the industry and market
- View opinions from our survey, discovering research interviews.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We tackle crucial questions on MS treatment, helping you to stay ahead.
Gain business research, data and analysis for multiple sclerosis drug treatments
Our report is for everybody needing industry and market analysis for drug-based MS treatment. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. EXECUTIVE SUMMARY
1.1 Multiple Sclerosis: Treatment Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO MULTIPLE SCLEROSIS AND ITS TREATMENT
2.1 The Pathology of Multiple Sclerosis
2.2 Diagnosis of MS
2.3 Measuring MS
2.4 The Different Types of Multiple Sclerosis
2.4.1 Relapsing Remitting MS
2.4.2 Secondary Progressive MS
2.4.3 Progressive Relapsing MS
2.4.4 Primary Progressive MS
2.4.5 Other Presentations of the Disease
2.5 Possible Causational Factors for MS
2.5.1 Genetic Factors
2.5.2 Infection
2.5.3 Environmental Factors and Less Well-Supported Theories
2.6 Demographics and Geographical Distribution
2.7 Economic Costs
2.8 Treatment Options
2.8.1 Treatment of Symptoms
2.8.2 Treatment of Attacks
2.8.3 Treatment of Disease Progression (Disease-Modifying Treatments)
2.8.4 Other Drugs and Off-Label Treatments
2.8.4.1 Rituxan (Rituximab, MabThera)
2.8.4.2 Campath (Alemtuzumab)
2.8.4.3 Novantrone (Mitoxantrone)
2.8.4.4 Imuran (Azothioprene)
2.8.4.5 Cyclophosphamide
2.8.4.6 Intravenous Immunoglobulin (IVIg)
2.8.4.7 Methotrexate (Maxtrex)
2.8.4.8 Low-Dose Naltrexone
2.8.5 Alternative Treatments
3. THE WORLD MARKET FOR MS DRUGS, 2011-2022
3.1 The MS Market in 2010
3.2 Copaxone Led the MS Drug Market in 2010
3.3 Together, Interferons Form Over Half the Market
3.4 Market Forecast, 2010-2022
3.4.1 The Impact of New Drugs on the MS Market
3.4.2 The Impact of Generic Drugs on the MS Market
4. LEADING NATIONAL MARKETS FOR MS DRUGS, 2011-2022
4.1 MS Drug Sales and Market Shares in Leading National Markets, 2010
4.2 Leading MS Markets: Sales Forecasts, 2011-2022
4.3 The US Is the Largest Market for MS Drugs
4.4 Europe
4.4.1 Germany Has the Largest EU Market for MS Drugs
4.4.2 France
4.4.3 Spain
4.4.4 Italy
4.4.5 The UK
4.5 Japan
4.6 India
4.7 China
5. DRUGS FOR TREATING MS: SALES PROSPECTS, 2011-2022
5.1 Copaxone
5.1.1 Copaxone Sales Forecast 2011-2022
5.1.2 Copaxone Will Benefit from Label Extension
5.2 Threat from Generic Competition for Copaxone
5.3 Avonex
5.3.1 Method of Use Patent Extension to 2026
5.3.2 PEG-Avonex
5.4 Rebif
5.5 Betaseron/Betaferon
5.6 Tysabri
5.6.1 PML and the JCV Assay
5.7 Extavia
5.8 Gilenya
5.8.1 Quarter-on-Quarter Growth of Gilenya
5.9 Biosimilars
6. LEADING COMPANIES IN THE MS DRUG INDUSTRY
6.1 Biogen Idec
6.1.1 Biogen Idec's Strong MS Pipeline
6.1.2 Biogen Has Licensed Ampyra, a Novel Treatment for MS Symptoms
6.1.3 The Threat of Biosimilars
6.2 Teva and Sanofi
6.2.1 Threats to Copaxone
6.2.1.1 Generic Competition for Copaxone
6.2.1.2 BG-12
6.2.1.3 Pipeline Copolymers
6.2.2 Opportunities for Copaxone
6.2.3 Extending Teva's MS Drug Franchise
6.3 Novartis
6.4 Merck Serono
6.5 Bayer
7. THE R&D PIPELINE FOR DISEASE-MODIFYING MS TREATMENT
7.1 MS Pipeline Drugs
7.2 Fast Forward
7.3 Modifications of Existing Drugs
7.3.1 PEG-INF (PEGylated Interferon Beta-1a)
7.3.2 NU100 (Interferon beta-1b) and NU400 (PEGylated Interferon Beta-1b)
7.3.3 Adjunct Therapies
7.4 Drugs that Regulate the Immune Response
7.4.1 Aubagio (Teriflunomide)
7.4.2 Laquinimod
7.4.3 Zanapax (Daclizumab)
7.4.4 Lemtrada/Campath (Alemtuzumab)
7.4.5 Oreclizumab
7.4.6 Trimesta
7.4.7 PI-2301
7.5 Anti-Inflammatory Drugs
7.5.1 BG-12 (Dimethyl Fumarate)
7.6 Drugs that Promote Remyelination
7.6.1 Olexisome
7.7 Vaccine Therapies
7.7.1 Tovaxin
7.7.2 BHT-3009
7.8 Stem Cell Treatment
7.9 Sativex
7.10 There is Strong Potential in the MS Drug Pipeline
8. FACTORS THAT INFLUENCE THE MS DRUG INDUSTRY AND MARKET
8.1 SWOT Analysis
8.2 Market Drivers
8.2.1 The MS Market Has Opportunities for Continuing Growth
8.2.2 Labelling Extensions for New Indications Can Drive Uptake
8.2.3 Competition Between Older and Newer Products
8.2.4 Other Services
8.2.5 Drug Preference
8.2.6 Advances in Technology Will Benefit Patients and the Market
8.2.6.1 Targeting Patient Subpopulations
8.2.7 The Rise of Comparative Studies
8.3 Market Restraints
8.3.1 The Threat of Generics and Biosimilars (Follow-on Biologics)
8.3.2 Cost Concerns
8.3.3 Off-Label Use and Risk-Sharing Schemes
8.3.4 Side Effects and Treatment Compliance
9. RESEARCH INTERVIEWS
9.1 Interview with Dr Karen M. Stockl (Prescription Solutions)
9.1.1 Improving Self-Management of MS
9.1.2 The Impact and Benefits of DTM Programmes
9.1.3 Improving Medication Adherence in MS Patients
9.1.4 Impact of Oral MS Medications
9.2 Interview with Dr Johan Luthman (Merck Serono)
9.2.1 On Understanding the Disease and its Treatments
9.2.2 On Unmet Needs for Treatment
9.2.3 On Current Treatment Options
9.2.4 On Medical Marijuana Use
9.2.5 On Oral Drugs
9.2.6 On Future Treatment Possibilities
9.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically Concerning Stem Cell Potential
9.3.1 On Stem Cell Media Coverage
9.3.2 On the Therapeutic and Curative Potential of Stem Cells for Neurological Disorders
9.3.3 On the Treatment of Neurological Disorders
9.3.4 On Stem Cell Treatment of MS: Viability, Curative Power, Treatment Strategy and Results
9.3.5 On the Time Frame for Marketable Stem Cell Treatment Options
10. CONCLUSIONS FROM THE STUDY
10.1 Growth of the MS Market Will Continue, But Will Be Limited by Competition
10.2 There Will Be Continued Growth in Leading Markets, Owing to New Products and Expanding Treatment Populations
10.3 There is a Strong R&D Pipeline for MS Treatment
10.4 Leading Companies in the MS Drug Market
10.5 Market Drivers
10.6 Market Restraints
10.7 Prospects for the MS Drug Market - Concluding Thoughts
1.1 Multiple Sclerosis: Treatment Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO MULTIPLE SCLEROSIS AND ITS TREATMENT
2.1 The Pathology of Multiple Sclerosis
2.2 Diagnosis of MS
2.3 Measuring MS
2.4 The Different Types of Multiple Sclerosis
2.4.1 Relapsing Remitting MS
2.4.2 Secondary Progressive MS
2.4.3 Progressive Relapsing MS
2.4.4 Primary Progressive MS
2.4.5 Other Presentations of the Disease
2.5 Possible Causational Factors for MS
2.5.1 Genetic Factors
2.5.2 Infection
2.5.3 Environmental Factors and Less Well-Supported Theories
2.6 Demographics and Geographical Distribution
2.7 Economic Costs
2.8 Treatment Options
2.8.1 Treatment of Symptoms
2.8.2 Treatment of Attacks
2.8.3 Treatment of Disease Progression (Disease-Modifying Treatments)
2.8.4 Other Drugs and Off-Label Treatments
2.8.4.1 Rituxan (Rituximab, MabThera)
2.8.4.2 Campath (Alemtuzumab)
2.8.4.3 Novantrone (Mitoxantrone)
2.8.4.4 Imuran (Azothioprene)
2.8.4.5 Cyclophosphamide
2.8.4.6 Intravenous Immunoglobulin (IVIg)
2.8.4.7 Methotrexate (Maxtrex)
2.8.4.8 Low-Dose Naltrexone
2.8.5 Alternative Treatments
3. THE WORLD MARKET FOR MS DRUGS, 2011-2022
3.1 The MS Market in 2010
3.2 Copaxone Led the MS Drug Market in 2010
3.3 Together, Interferons Form Over Half the Market
3.4 Market Forecast, 2010-2022
3.4.1 The Impact of New Drugs on the MS Market
3.4.2 The Impact of Generic Drugs on the MS Market
4. LEADING NATIONAL MARKETS FOR MS DRUGS, 2011-2022
4.1 MS Drug Sales and Market Shares in Leading National Markets, 2010
4.2 Leading MS Markets: Sales Forecasts, 2011-2022
4.3 The US Is the Largest Market for MS Drugs
4.4 Europe
4.4.1 Germany Has the Largest EU Market for MS Drugs
4.4.2 France
4.4.3 Spain
4.4.4 Italy
4.4.5 The UK
4.5 Japan
4.6 India
4.7 China
5. DRUGS FOR TREATING MS: SALES PROSPECTS, 2011-2022
5.1 Copaxone
5.1.1 Copaxone Sales Forecast 2011-2022
5.1.2 Copaxone Will Benefit from Label Extension
5.2 Threat from Generic Competition for Copaxone
5.3 Avonex
5.3.1 Method of Use Patent Extension to 2026
5.3.2 PEG-Avonex
5.4 Rebif
5.5 Betaseron/Betaferon
5.6 Tysabri
5.6.1 PML and the JCV Assay
5.7 Extavia
5.8 Gilenya
5.8.1 Quarter-on-Quarter Growth of Gilenya
5.9 Biosimilars
6. LEADING COMPANIES IN THE MS DRUG INDUSTRY
6.1 Biogen Idec
6.1.1 Biogen Idec's Strong MS Pipeline
6.1.2 Biogen Has Licensed Ampyra, a Novel Treatment for MS Symptoms
6.1.3 The Threat of Biosimilars
6.2 Teva and Sanofi
6.2.1 Threats to Copaxone
6.2.1.1 Generic Competition for Copaxone
6.2.1.2 BG-12
6.2.1.3 Pipeline Copolymers
6.2.2 Opportunities for Copaxone
6.2.3 Extending Teva's MS Drug Franchise
6.3 Novartis
6.4 Merck Serono
6.5 Bayer
7. THE R&D PIPELINE FOR DISEASE-MODIFYING MS TREATMENT
7.1 MS Pipeline Drugs
7.2 Fast Forward
7.3 Modifications of Existing Drugs
7.3.1 PEG-INF (PEGylated Interferon Beta-1a)
7.3.2 NU100 (Interferon beta-1b) and NU400 (PEGylated Interferon Beta-1b)
7.3.3 Adjunct Therapies
7.4 Drugs that Regulate the Immune Response
7.4.1 Aubagio (Teriflunomide)
7.4.2 Laquinimod
7.4.3 Zanapax (Daclizumab)
7.4.4 Lemtrada/Campath (Alemtuzumab)
7.4.5 Oreclizumab
7.4.6 Trimesta
7.4.7 PI-2301
7.5 Anti-Inflammatory Drugs
7.5.1 BG-12 (Dimethyl Fumarate)
7.6 Drugs that Promote Remyelination
7.6.1 Olexisome
7.7 Vaccine Therapies
7.7.1 Tovaxin
7.7.2 BHT-3009
7.8 Stem Cell Treatment
7.9 Sativex
7.10 There is Strong Potential in the MS Drug Pipeline
8. FACTORS THAT INFLUENCE THE MS DRUG INDUSTRY AND MARKET
8.1 SWOT Analysis
8.2 Market Drivers
8.2.1 The MS Market Has Opportunities for Continuing Growth
8.2.2 Labelling Extensions for New Indications Can Drive Uptake
8.2.3 Competition Between Older and Newer Products
8.2.4 Other Services
8.2.5 Drug Preference
8.2.6 Advances in Technology Will Benefit Patients and the Market
8.2.6.1 Targeting Patient Subpopulations
8.2.7 The Rise of Comparative Studies
8.3 Market Restraints
8.3.1 The Threat of Generics and Biosimilars (Follow-on Biologics)
8.3.2 Cost Concerns
8.3.3 Off-Label Use and Risk-Sharing Schemes
8.3.4 Side Effects and Treatment Compliance
9. RESEARCH INTERVIEWS
9.1 Interview with Dr Karen M. Stockl (Prescription Solutions)
9.1.1 Improving Self-Management of MS
9.1.2 The Impact and Benefits of DTM Programmes
9.1.3 Improving Medication Adherence in MS Patients
9.1.4 Impact of Oral MS Medications
9.2 Interview with Dr Johan Luthman (Merck Serono)
9.2.1 On Understanding the Disease and its Treatments
9.2.2 On Unmet Needs for Treatment
9.2.3 On Current Treatment Options
9.2.4 On Medical Marijuana Use
9.2.5 On Oral Drugs
9.2.6 On Future Treatment Possibilities
9.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically Concerning Stem Cell Potential
9.3.1 On Stem Cell Media Coverage
9.3.2 On the Therapeutic and Curative Potential of Stem Cells for Neurological Disorders
9.3.3 On the Treatment of Neurological Disorders
9.3.4 On Stem Cell Treatment of MS: Viability, Curative Power, Treatment Strategy and Results
9.3.5 On the Time Frame for Marketable Stem Cell Treatment Options
10. CONCLUSIONS FROM THE STUDY
10.1 Growth of the MS Market Will Continue, But Will Be Limited by Competition
10.2 There Will Be Continued Growth in Leading Markets, Owing to New Products and Expanding Treatment Populations
10.3 There is a Strong R&D Pipeline for MS Treatment
10.4 Leading Companies in the MS Drug Market
10.5 Market Drivers
10.6 Market Restraints
10.7 Prospects for the MS Drug Market - Concluding Thoughts
LIST OF TABLES
Table 2.1 The Kurtzke Expanded Disability Scales (EDSS)
Table 2.2 Multiple Sclerosis Populations and Prevalence for Leading Countries, 2011
Table 2.3 Licensed Disease Modifying Drugs for Multiple Sclerosis, 2011
Table 3.1 Disease-Modifying Drug Sales, 2010
Table 3.2 Sales of MS Drugs by Type, 2010
Table 3.3 MS Drug Forecasts, 2010-2015
Table 3.4 MS Drug Forecasts, 2016-2022
Table 3.5 Current Leading Multiple Sclerosis Drugs: Forecast Revenues, 2022
Table 4.1 Leading MS Markets by Country: Sales and Market Shares, 2010
Table 4.2 Leading MS Markets: Revenue Forecasts by Country, 2010-2015
Table 4.3 Leading MS Markets: Revenue Forecasts by Country, 2016-2022
Table 4.4 US MS Drug Revenues, 2010-2022
Table 4.5 German MS Drug Revenues, 2010-2022
Table 4.6 French MS Drug Revenues, 2010-2022
Table 4.7 Spanish MS Drug Revenues, 2010-2022
Table 4.8 Italian MS Drug Revenues, 2010-2022
Table 4.9 UK MS Drug Revenues, 2010-2022
Table 4.10 Japanese MS Drug Revenues, 2010-2022
Table 4.11 Indian MS Drug Revenues, 2010-2022
Table 4.12 Chinese MS Drug Revenues, 2010-2022
Table 5.1 Copaxone Revenues, 2010-2022
Table 5.2 Avonex Revenues, 2010-2022
Table 5.3 Rebif Revenues, 2010-2022
Table 5.4 Betaseron/Betaferon Revenues, 2010-2022
Table 5.5 Tysabri Revenues, 2010-2022
Table 5.6 Extavia Revenues, 2010-2022
Table 5.7 Gilenya Revenues, 2010-2022
Table 6.1 MS Drugs and Their Producers, 2010
Table 6.2 MS Drug Producers' Revenues, 2010
Table 6.3 Biogen Idec Multiple Sclerosis Drug Pipeline, 2011
Table 7.1 The Multiple Sclerosis Disease-Modifying Drug Pipeline, 2011
Table 7.2 Preclinical Disease-Modifying Multiple Sclerosis Agents, 2011
Table 8.1 SWOT Analysis of the MS Drug Industry and Market, 2011
Table 8.2 Numbers of Medical MRI Scanners per 1,000,000 of Population for Leading MS Treatment Markets
Table 2.1 The Kurtzke Expanded Disability Scales (EDSS)
Table 2.2 Multiple Sclerosis Populations and Prevalence for Leading Countries, 2011
Table 2.3 Licensed Disease Modifying Drugs for Multiple Sclerosis, 2011
Table 3.1 Disease-Modifying Drug Sales, 2010
Table 3.2 Sales of MS Drugs by Type, 2010
Table 3.3 MS Drug Forecasts, 2010-2015
Table 3.4 MS Drug Forecasts, 2016-2022
Table 3.5 Current Leading Multiple Sclerosis Drugs: Forecast Revenues, 2022
Table 4.1 Leading MS Markets by Country: Sales and Market Shares, 2010
Table 4.2 Leading MS Markets: Revenue Forecasts by Country, 2010-2015
Table 4.3 Leading MS Markets: Revenue Forecasts by Country, 2016-2022
Table 4.4 US MS Drug Revenues, 2010-2022
Table 4.5 German MS Drug Revenues, 2010-2022
Table 4.6 French MS Drug Revenues, 2010-2022
Table 4.7 Spanish MS Drug Revenues, 2010-2022
Table 4.8 Italian MS Drug Revenues, 2010-2022
Table 4.9 UK MS Drug Revenues, 2010-2022
Table 4.10 Japanese MS Drug Revenues, 2010-2022
Table 4.11 Indian MS Drug Revenues, 2010-2022
Table 4.12 Chinese MS Drug Revenues, 2010-2022
Table 5.1 Copaxone Revenues, 2010-2022
Table 5.2 Avonex Revenues, 2010-2022
Table 5.3 Rebif Revenues, 2010-2022
Table 5.4 Betaseron/Betaferon Revenues, 2010-2022
Table 5.5 Tysabri Revenues, 2010-2022
Table 5.6 Extavia Revenues, 2010-2022
Table 5.7 Gilenya Revenues, 2010-2022
Table 6.1 MS Drugs and Their Producers, 2010
Table 6.2 MS Drug Producers' Revenues, 2010
Table 6.3 Biogen Idec Multiple Sclerosis Drug Pipeline, 2011
Table 7.1 The Multiple Sclerosis Disease-Modifying Drug Pipeline, 2011
Table 7.2 Preclinical Disease-Modifying Multiple Sclerosis Agents, 2011
Table 8.1 SWOT Analysis of the MS Drug Industry and Market, 2011
Table 8.2 Numbers of Medical MRI Scanners per 1,000,000 of Population for Leading MS Treatment Markets
LIST OF FIGURES
Figure 3.1 Breakdown of the Multiple Sclerosis Market by Drug, 2010
Figure 3.2 MS Drug Market Forecast, 2010-2022
Figure 3.3 MS Drug Forecasts, 2010-2022
Figure 3.4 MS Drug Revenues and Market Shares, 2022
Figure 4.1 MS Drug Market Shares by Leading Country, 2010
Figure 4.2 US MS Drug Revenues, 2010-2022
Figure 4.3 German MS Drug Revenues, 2010-2022
Figure 4.4 French MS Drug Revenues, 2010-2022
Figure 4.5 Spanish MS Drug Revenues, 2010-2022
Figure 4.6 Italian MS Drug Revenues, 2010-2022
Figure 4.7 UK MS Drug Revenues, 2010-2022
Figure 4.8 Japanese MS Drug Revenues, 2010-2022
Figure 4.9 Indian MS Drug Revenues, 2010-2022
Figure 4.10 Chinese MS Drug Revenues, 2010-2022
Figure 5.1 Copaxone Revenues, 2010-2022
Figure 5.2 Avonex Revenues, 2010-2022
Figure 5.3 Rebif Revenues, 2010-2022
Figure 5.4 Betaseron/Betaferon Revenues, 2010-2022
Figure 5.5 Tysabri Revenues, 2010-2022
Figure 5.6 Extavia Revenues, 2010-2022
Figure 5.7 Gilenya Revenues, 2010-2022
Figure 5.8 Gilenya Sales, Q4 2010-Q3 2011
COMPANIES LISTED
AB Science SA
Abbott Laboratories
Accentia
Acorda Therapeutics
Actelion
Active Biotech
Adeona
Advancell
Allozyne
Ambrx
Amplimmune
Apitope
Artielle Immunotherapeutics
Athersys
Axxam
Barofold
Baxter Healthcare Corporation
Bayer Schering
Bayhill Therapeutics
Biogen Idec
BioMS Medical Corp
Bionomics
Biopartners
Biotest
Biovista
BTG
Canbex Therapeutics
Celgene
Cell Therapeutics
CenTRion Therapeutics
Charite University
Chiron
Chromos Molecular Systems
CinnaGens
Clinical Data
Cognosci
Compugen
Daiichi Sankyo
Duke University
Elan Pharmaceuticals
European Medicines Agency (EMA)
Evotec
Fast Forward
FivePrime Therapeutics
Food and Drug Administration (FDA, US)
Genentech
GeNeuro
Genmab
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
GTC Biotherapeutics
GW Pharmaceuticals
Hard to Treat Diseases (HTDS)
Hemispherx Biopharma
Henry Ford Health System
Hospices Civils de Lyon
Howard Florey Institute
Immune Tolerance Network
Innate Therapeutics
International Multiple Sclerosis Management Practice
Jewish General Hospital Lady David Institute
Kineta
Landsteiner
LTKFarma
McGill University
MediciNova
Merck KGaA
Merck Serono
Momenta Pharmaceuticals
Multiple Sclerosis Research Center of New York
Multiple Sclerosis Trust (UK)
Mylan
Natco Pharma
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases
National Institute of Neurological Disorders and Strokes
National Institutes of Health Clinical Centre
National Multiple Sclerosis Society (US)
Neurotec Pharma
Northwestern University
Novartis
NovImmune
Nuron
Ono Pharmaceutical Co.
Opexa Therapeutics
Oregon Health & Science University
Peninsula College of Medicine and Dentistry, Clinical Neurology Research and Trials Group
Peptimmune
Pfizer
Pluristem Therapeutics
Prescription Solutions
Probiomed
ProtAffin
Provid Pharmaceuticals
Purdue University
Receptopharm
Receptos
RegeneRX
Roche
Rush University Medical Centre
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co
ScreeningPort
Slavica Biochem
Stem Cell Network (Canada)
Stem Cell Therapeutics
SUNY Downstate Medical Centre
SuppreMol
Teva Pharmaceutical Industries
The Gladstone Institutes
Trophos
UC Boulder
United States National Multiple Sclerosis Society
University of Calgary
University of California Davis
University of California San Francisco
University of Louisville
University of Sao Paolo
Uppsala University
World Health Organization (WHO)
Figure 3.1 Breakdown of the Multiple Sclerosis Market by Drug, 2010
Figure 3.2 MS Drug Market Forecast, 2010-2022
Figure 3.3 MS Drug Forecasts, 2010-2022
Figure 3.4 MS Drug Revenues and Market Shares, 2022
Figure 4.1 MS Drug Market Shares by Leading Country, 2010
Figure 4.2 US MS Drug Revenues, 2010-2022
Figure 4.3 German MS Drug Revenues, 2010-2022
Figure 4.4 French MS Drug Revenues, 2010-2022
Figure 4.5 Spanish MS Drug Revenues, 2010-2022
Figure 4.6 Italian MS Drug Revenues, 2010-2022
Figure 4.7 UK MS Drug Revenues, 2010-2022
Figure 4.8 Japanese MS Drug Revenues, 2010-2022
Figure 4.9 Indian MS Drug Revenues, 2010-2022
Figure 4.10 Chinese MS Drug Revenues, 2010-2022
Figure 5.1 Copaxone Revenues, 2010-2022
Figure 5.2 Avonex Revenues, 2010-2022
Figure 5.3 Rebif Revenues, 2010-2022
Figure 5.4 Betaseron/Betaferon Revenues, 2010-2022
Figure 5.5 Tysabri Revenues, 2010-2022
Figure 5.6 Extavia Revenues, 2010-2022
Figure 5.7 Gilenya Revenues, 2010-2022
Figure 5.8 Gilenya Sales, Q4 2010-Q3 2011
COMPANIES LISTED
AB Science SA
Abbott Laboratories
Accentia
Acorda Therapeutics
Actelion
Active Biotech
Adeona
Advancell
Allozyne
Ambrx
Amplimmune
Apitope
Artielle Immunotherapeutics
Athersys
Axxam
Barofold
Baxter Healthcare Corporation
Bayer Schering
Bayhill Therapeutics
Biogen Idec
BioMS Medical Corp
Bionomics
Biopartners
Biotest
Biovista
BTG
Canbex Therapeutics
Celgene
Cell Therapeutics
CenTRion Therapeutics
Charite University
Chiron
Chromos Molecular Systems
CinnaGens
Clinical Data
Cognosci
Compugen
Daiichi Sankyo
Duke University
Elan Pharmaceuticals
European Medicines Agency (EMA)
Evotec
Fast Forward
FivePrime Therapeutics
Food and Drug Administration (FDA, US)
Genentech
GeNeuro
Genmab
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
GTC Biotherapeutics
GW Pharmaceuticals
Hard to Treat Diseases (HTDS)
Hemispherx Biopharma
Henry Ford Health System
Hospices Civils de Lyon
Howard Florey Institute
Immune Tolerance Network
Innate Therapeutics
International Multiple Sclerosis Management Practice
Jewish General Hospital Lady David Institute
Kineta
Landsteiner
LTKFarma
McGill University
MediciNova
Merck KGaA
Merck Serono
Momenta Pharmaceuticals
Multiple Sclerosis Research Center of New York
Multiple Sclerosis Trust (UK)
Mylan
Natco Pharma
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases
National Institute of Neurological Disorders and Strokes
National Institutes of Health Clinical Centre
National Multiple Sclerosis Society (US)
Neurotec Pharma
Northwestern University
Novartis
NovImmune
Nuron
Ono Pharmaceutical Co.
Opexa Therapeutics
Oregon Health & Science University
Peninsula College of Medicine and Dentistry, Clinical Neurology Research and Trials Group
Peptimmune
Pfizer
Pluristem Therapeutics
Prescription Solutions
Probiomed
ProtAffin
Provid Pharmaceuticals
Purdue University
Receptopharm
Receptos
RegeneRX
Roche
Rush University Medical Centre
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co
ScreeningPort
Slavica Biochem
Stem Cell Network (Canada)
Stem Cell Therapeutics
SUNY Downstate Medical Centre
SuppreMol
Teva Pharmaceutical Industries
The Gladstone Institutes
Trophos
UC Boulder
United States National Multiple Sclerosis Society
University of Calgary
University of California Davis
University of California San Francisco
University of Louisville
University of Sao Paolo
Uppsala University
World Health Organization (WHO)
